Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANR007
MIFTS: 62

Anorexia Nervosa

Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anorexia Nervosa

About this section

MalaCards integrated aliases for Anorexia Nervosa:

Name: Anorexia Nervosa 57 12 76 55 44 15 73
Anorexia Nervosa, Susceptibility to, 1 57 13 40
Anorexia Nervosa, Susceptibility to 57 13
Anorexia Nervosa 1 57 29
Anon 57
an 57

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 606788
Disease Ontology 12 DOID:8689
ICD10 33 F50.0 F50.00
ICD9CM 35 307.1
MeSH 44 D000856
NCIt 50 C34387
UMLS 73 C0003125
Sources

Summaries for Anorexia Nervosa

About this section
OMIM : 57 Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788)

MalaCards based summary : Anorexia Nervosa, also known as anorexia nervosa, susceptibility to, 1, is related to acanthosis nigricans and amenorrhea, and has symptoms including decrease in appetite An important gene associated with Anorexia Nervosa is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Fluoxetine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and heart, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

Wikipedia : 76 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low... more...

Sources

Related Diseases for Anorexia Nervosa

About this section

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 acanthosis nigricans 33.3 ADIPOQ IGF1 LEP PRL
2 amenorrhea 31.6 CRH LEP POMC PRL
3 personality disorder 31.5 BDNF HTR2A SLC6A4
4 obsessive-compulsive disorder 31.5 BDNF HTR2A PRL SLC6A4
5 depression 31.4 BDNF CRH HTR2A SLC6A4
6 bulimia nervosa 31.2 BDNF CCK GHRL HTR2A LEP NPY
7 eating disorder 31.2 ADIPOQ BDNF CCK CRH GHRL LEP
8 borderline personality disorder 31.2 BDNF HTR2A SLC6A4
9 generalized anxiety disorder 31.1 BDNF HTR2A SLC6A4
10 hyperinsulinism 31.0 GH1 GHRL IGF1 LEP
11 anxiety 30.9 BDNF CCK CRH HTR2A NPY SLC6A4
12 craniopharyngioma 30.8 GH1 GHRL IGF1 PRL
13 hyperthyroidism 30.8 GH1 GHRL LEP PRL
14 alcohol abuse 30.8 BDNF PRL SLC6A4
15 substance abuse 30.8 BDNF NPY PRL SLC6A4
16 chronic fatigue syndrome 30.7 CRH IGF1 POMC SLC6A4
17 diabetes insipidus 30.6 CRH POMC PRL
18 endogenous depression 30.5 BDNF CRH POMC SLC6A4
19 drug dependence 30.5 BDNF CRH POMC SLC6A4
20 growth hormone deficiency 30.4 GH1 GHRH GHRL IGF1
21 osteoporosis 30.4 GH1 GHR IGF1 LEP LEPR
22 morbid obesity 30.2 ADIPOQ CCK GHRL LEP LEPR PYY
23 dwarfism 30.2 GH1 GHR GHRH
24 insulin-like growth factor i 30.2 GH1 GHR GHRH IGF1 LEP PRL
25 schizophrenia 30.1 BDNF CCK HTR2A NPY PRL SLC6A4
26 isolated growth hormone deficiency 30.1 GH1 GHR GHRH IGF1
27 major depressive disorder 30.0 BDNF CRH HTR2A NPY POMC PRL
28 bipolar disorder 29.9 BDNF CRH HTR2A IGF1 PRL SLC6A4
29 hypothalamic disease 29.8 CRH GH1 GHRH POMC PRL
30 hypopituitarism 29.5 CRH GH1 GHRH IGF1 POMC PRL
31 diabetes mellitus, noninsulin-dependent 29.4 ADIPOQ GH1 GHRL IGF1 LEP LEPR
32 adrenal gland hyperfunction 29.3 CRH GH1 GHRH GHRL LEP POMC
33 prader-willi syndrome 27.5 ADIPOQ AGRP CCK GH1 GHR GHRL
34 hair-an syndrome 12.2
35 hemophagocytic syndrome associated with an infection 12.0
36 systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 12.0
37 sickle cell disease associated with an other hemoglobin anomaly 11.9
38 silver-russell syndrome due to an imprinting defect of 11p15 11.9
39 blood group--ahonen 11.7
40 body dysmorphic disorder 11.5
41 aniridia 1 11.5
42 pili torti 11.4
43 acute necrotizing encephalopathy 11.4
44 encephalopathy, acute, infection-induced 4 11.3
45 schizophrenia 1 11.3
46 fibrous dysplasia/mccune-albright syndrome 11.0 GH1 PRL
47 acidophil adenoma 11.0 IGF1 POMC
48 alzheimer disease 5 11.0 HTR2A SLC6A4
49 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.0 LEP POMC
50 pituitary infarct 10.9 IGF1 POMC PRL

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa
Sources

Symptoms & Phenotypes for Anorexia Nervosa

About this section

Clinical features from OMIM:

606788

UMLS symptoms related to Anorexia Nervosa:


decrease in appetite

GenomeRNAi Phenotypes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGRP BDNF GHR GHRL IGF1 POMC

MGI Mouse Phenotypes related to Anorexia Nervosa:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 CCK ADIPOQ CRH AGRP GHR BDNF
2 homeostasis/metabolism MP:0005376 10.39 GHRH CCK ADIPOQ CRH AGRP GHR
3 endocrine/exocrine gland MP:0005379 10.34 GHRH CCK ADIPOQ CRH GHR BDNF
4 adipose tissue MP:0005375 10.3 ADIPOQ CRH AGRP GHR GHRL LEPR
5 growth/size/body region MP:0005378 10.29 BDNF ADIPOQ CRH AGRP GHR LEP
6 liver/biliary system MP:0005370 10.14 GHRH ADIPOQ CRH AGRP GHR LEPR
7 integument MP:0010771 10.13 ADIPOQ CRH GHR BDNF LEPR IGF1
8 nervous system MP:0003631 10.1 GHRH CCK CRH AGRP GHR BDNF
9 muscle MP:0005369 9.91 GHR ADIPOQ LEP HTR2A LEPR IGF1
10 normal MP:0002873 9.81 BDNF CRH AGRP GHRL LEPR IGF1
11 neoplasm MP:0002006 9.8 ADIPOQ LEP LEPR IGF1 POMC PRL
12 renal/urinary system MP:0005367 9.61 CCK ADIPOQ CRH GHR LEPR IGF1
13 skeleton MP:0005390 9.28 ADIPOQ CRH GHR LEP HTR2A LEPR
Sources

Drugs & Therapeutics for Anorexia Nervosa

About this section

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
2
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
4
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
7
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
8 Raclopride Investigational Phase 4 84225-95-6
9 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
14 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
16 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antidepressive Agents Phase 4,Not Applicable
18 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
19 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Not Applicable
20 Cytochrome P-450 Enzyme Inhibitors Phase 4,Not Applicable
21 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 Dopamine Agents Phase 4,Not Applicable
26 Dopamine Antagonists Phase 4
27 Serotonin Antagonists Phase 4
28 Adrenergic Agents Phase 4,Not Applicable
29 Central Nervous System Stimulants Phase 4
30 Dopamine Uptake Inhibitors Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
32
Teriparatide Approved, Investigational Phase 3,Phase 2 52232-67-4 16133850
33
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 50-28-2 5757
34 Estradiol valerate Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 979-32-8
35
Ethinyl Estradiol Approved Phase 2, Phase 3,Phase 3 57-63-6 5991
36
Medroxyprogesterone acetate Approved, Investigational Phase 2, Phase 3,Phase 1 71-58-9
37
Polyestradiol phosphate Approved Phase 2, Phase 3,Phase 3,Phase 1 28014-46-2
38
Progesterone Approved, Vet_approved Phase 2, Phase 3,Phase 3 57-83-0 5994
39
Epinephrine Approved, Vet_approved Phase 2, Phase 3,Phase 3 51-43-4 5816
40
Levonorgestrel Approved, Investigational Phase 2, Phase 3,Phase 3 797-63-7, 17489-40-6 13109
41
Racepinephrine Approved Phase 2, Phase 3,Phase 3 329-65-7 838
42
Etidronic acid Approved Phase 2, Phase 3,Not Applicable 7414-83-7, 2809-21-4 3305
43
Methyltestosterone Approved Phase 2, Phase 3,Not Applicable 58-18-4 6010
44
Testosterone Approved, Investigational Phase 2, Phase 3,Not Applicable 58-22-0 6013
45
Testosterone enanthate Approved Phase 2, Phase 3,Not Applicable 315-37-7 9416
46
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3,Not Applicable 5949-44-0
47
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
48
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
49
Denosumab Approved Phase 3,Early Phase 1 615258-40-7
50
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 53-43-0 9860744

Interventional clinical trials:

(show top 50) (show all 222)
# Name Status NCT ID Phase Drugs
1 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
2 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
3 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
4 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
5 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
6 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
7 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
8 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
10 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
11 Effects of Anorexia Nervosa on Bone Mass in Adolescents Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
12 Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
13 The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa Completed NCT02004288 Phase 2, Phase 3
14 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
15 Bone Loss in Women With Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
16 Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
17 Hormonal Therapy for Teens With Anorexia Nervosa Completed NCT01343771 Phase 3 DHEA (Prasterone) + ERT (Aviane)
18 Effects of Anorexia Nervosa on Peak Bone Mass Recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
19 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Recruiting NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
20 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
21 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3 Olanzapine
22 Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Unknown status NCT01761942 Phase 2
23 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa Unknown status NCT01611220 Phase 2
24 Therapeutic Effects of Neurofeedback in Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
25 Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
26 A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
27 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
28 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
29 Olanzapine in the Treatment of Patients With Anorexia Nervosa Completed NCT00260962 Phase 2 Olanzapine
30 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
31 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
32 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
33 Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Completed NCT00183586 Phase 2
34 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
35 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
36 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
37 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
38 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Recruiting NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
39 Estrogen Replacement in Anorexia Nervosa Recruiting NCT03172533 Phase 2 ethinyl estradiol 0.03mg and dienogest 2 mg (combination);Placebo oral capsule
40 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2 quetiapine
41 The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2 testosterone cypionate
42 Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
43 Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01476540 Phase 1
44 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01678014 Phase 1
45 Yoga in Treatment of Eating Disorders Unknown status NCT00870753 Phase 1
46 Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa Completed NCT00601822 Phase 1
47 Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1
48 Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa Completed NCT00149786 Phase 1
49 Estradiol and Fear Extinction in Anorexia Nervosa (AN) Recruiting NCT02792153 Phase 1 Estradiol
50 Lung Function Tests in Adolescents With Anorexia Nervosa Unknown status NCT00942929

Search NIH Clinical Center for Anorexia Nervosa

Cochrane evidence based reviews: anorexia nervosa

Sources

Genetic Tests for Anorexia Nervosa

About this section

Genetic tests related to Anorexia Nervosa:

# Genetic test Affiliating Genes
1 Anorexia Nervosa 1 29 HTR2A
Sources

Anatomical Context for Anorexia Nervosa

About this section

MalaCards organs/tissues related to Anorexia Nervosa:

41
Bone, Brain, Heart, Testes, Liver, Pituitary, Lung
Sources

Publications for Anorexia Nervosa

About this section

Articles related to Anorexia Nervosa:

(show top 50) (show all 1439)
# Title Authors Year
1
Role of antidepressants in the treatment of adults with anorexia nervosa. ( 29955558 )
2018
2
Do eating disorder voice characteristics predict treatment outcomes in anorexia nervosa? A pilot study. ( 29882721 )
2018
3
Do autism spectrum disorder and anorexia nervosa have some eating disturbances in common? ( 29974245 )
2018
4
Associations between exercise, bone mineral density, and body composition in adolescents with anorexia nervosa. ( 29949128 )
2018
5
Anorexia Nervosa, Selflessness, and Gender-role Identity: A Study of Daughters and Parents. ( 29916404 )
2018
6
The QT Interval in Anorexia Nervosa: A Meta-Analysis. ( 29929679 )
2018
7
Anorexia nervosa-associated pancytopenia mimicking idiopathic aplastic anemia: a case report. ( 29801443 )
2018
8
The role of maternal anorexia nervosa and bulimia nervosa before and during pregnancy in early childhood wheezing: Findings from the NINFEA birth cohort study. ( 29722053 )
2018
9
Women with Anorexia Nervosa do not show altered tactile localization compared to healthy controls. ( 29980123 )
2018
10
In Reply: Long-Term Follow-up Study of MRI-Guided Bilateral Anterior Capsulotomy in Patients With Refractory Anorexia Nervosa. ( 29912441 )
2018
11
White matter microstructure in anorexia nervosa. ( 29964345 )
2018
12
Testing the relative associations of different components of dietary restraint on psychological functioning in anorexia nervosa and bulimia nervosa. ( 29807122 )
2018
13
Locating the mechanisms of therapeutic agency in family-based treatment for adolescent anorexia nervosa: A pilot study of clinician/researcher perspectives. ( 29863443 )
2018
14
Differential Diagnoses of Food-Related Gastrointestinal Symptoms in Patients with Anorexia Nervosa and Bulimia Nervosa: A Review of Literature. ( 29498331 )
2018
15
Bone Parameters in Anorexia Nervosa and Athletic Amenorrhea: Comparison of Two Hypothalamic Amenorrhea States. ( 29659886 )
2018
16
Non-weight-related body image concerns and Body Dysmorphic Disorder prevalence in patients with Anorexia Nervosa. ( 29886274 )
2018
17
Validation of the Inventory of Interpersonal Problems (IIP-64): a comparison of Swedish female outpatients with anorexia nervosa or bulimia nervosa and controls. ( 29703121 )
2018
18
Symptomatology long-term evolution after hospitalization for anorexia nervosa: Drive for thinness to explain effects of body dissatisfaction on type of outcome. ( 29859637 )
2018
19
Associations among eating disorder behaviors and eating disorder quality of life in adult women with anorexia nervosa. ( 29886272 )
2018
20
Feeling fat in eating disorders: Testing the unique relationships between feeling fat and measures of disordered eating in anorexia nervosa and bulimia nervosa. ( 29653375 )
2018
21
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
22
Letter: Long-Term Follow-up Study of MRI-Guided Bilateral Anterior Capsulotomy in Patients With Refractory Anorexia Nervosa. ( 29912370 )
2018
23
Nutritional Status Affects Cortical Folding: Lessons Learned From Anorexia Nervosa. ( 29910027 )
2018
24
Deranged emotional and cortisol responses to a psychosocial stressor in anorexia nervosa women with childhood trauma exposure: Evidence for a "maltreated ecophenotype"? ( 29936175 )
2018
25
Core psychopathology in anorexia nervosa and bulimia nervosa: A network analysis. ( 29693747 )
2018
26
The Impact of Alexithymia on Emotion Dysregulation in Anorexia Nervosa and Bulimia Nervosa over Time. ( 29266572 )
2018
27
Altered cerebellar-insular-parietal-cingular subnetwork in adolescents in the earliest stages of anorexia nervosa: a network-based statistic analysis. ( 29980676 )
2018
28
Implementation of enhanced cognitive behaviour therapy (CBT-E) for adults with anorexia nervosa in an outpatient eating-disorder unit at a public hospital. ( 29854400 )
2018
29
Clinical characteristics of early onset anorexia nervosa. ( 29943460 )
2018
30
Effects of starvation and short-term refeeding on gastric emptying and postprandial blood glucose regulation in adolescent females with anorexia nervosa. ( 29969316 )
2018
31
Metabolic Barriers to Weight Gain in Patients With Anorexia Nervosa: A Young Adult Case Report. ( 29867616 )
2018
32
Fifty years of anorexia nervosa and other eating disorders in the Australian & New Zealand Journal of Psychiatry. ( 28521537 )
2017
33
Effects of Anorexia Nervosa on the Endocrine System. ( 28508601 )
2017
34
Ammonium acid urate urolithiasis in anorexia nervosa: a case report and literature review. ( 28469876 )
2017
35
Association of the 5-HT<sub>2A</sub> receptor gene promoter polymorphism-1438G/A with anorexia nervosa and psychopathological traits in the Chinese Han population: A preliminary study. ( 28639321 )
2017
36
Membranous tracheal stenosis in a patient with anorexia nervosa and self-induced vomiting- challenges in securing the airway. ( 28377879 )
2017
37
Anorexia nervosa and bulimia nervosa: A meta-analysis of executive functioning. ( 28851577 )
2017
38
Ehlers-Danlos syndrome in a young woman with anorexia nervosa and complex somatic symptoms. ( 29247552 )
2017
39
Acute retropharyngeal abscess in a patient with anorexia nervosa. ( 28058633 )
2017
40
A dark past, a restrained present, and an apocalyptic future: time perspective, personality, and life satisfaction among anorexia nervosa patients. ( 28929023 )
2017
41
Themes arising in clinical consultation for therapists implementing family-based treatment for adolescents with anorexia nervosa: a qualitative study. ( 28878927 )
2017
42
Metasynthesis of the Views about Treatment of Anorexia Nervosa in Adolescents: Perspectives of Adolescents, Parents, and Professionals. ( 28056106 )
2017
43
Transition Care in Anorexia Nervosa Through Guidance Online from Peer and Carer Expertise (TRIANGLE): Study Protocol for a Randomised Controlled Trial. ( 28944595 )
2017
44
Modeling anorexia nervosa: transcriptional insights from human iPSC-derived neurons. ( 28291261 )
2017
45
Plasma BDNF levels and anxiety in women with recovery from anorexia nervosa. ( 28522315 )
2017
46
Anxiolytic effect of warmth in anorexia nervosa. ( 28043086 )
2017
47
Nephrocalcinosis in a young male with anorexia nervosa. ( 28669007 )
2017
48
Markers of Cardiovascular Dysfunction in Adolescents With Anorexia Nervosa. ( 28890913 )
2017
49
Treatment with granulocyte colony-stimulating factor in the refeeding phase of anorexia nervosa complicated with severe neutropenia and sepsis: a case report. ( 28871553 )
2017
50
Hepatic Complications of Anorexia Nervosa. ( 28932925 )
2017
Sources

Variations for Anorexia Nervosa

About this section
Sources

Expression for Anorexia Nervosa

About this section
Search GEO for disease gene expression data for Anorexia Nervosa.
Sources

Pathways for Anorexia Nervosa

About this section

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 66
Show member pathways
 13.04 CCK CRH GH1 GHR GHRH GHRL
2
G-Beta Gamma Signaling 64
Show member pathways
 12.84 BDNF CRH GH1 GHRH HTR2A POMC
3
Regulation of IFNA signaling 66
Show member pathways
 12.4 GH1 GHR LEP LEPR PRL
4
Prolactin Signaling Pathway 1 37
Show member pathways
 12.29 GH1 LEP LEPR PRL
5
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.24 ADIPOQ IGF1 LEP LEPR
7
Peptide hormone metabolism 66
Show member pathways
 11.98 GH1 GHRL IGF1 LEP POMC
8
Adipogenesis 1
11.78 ADIPOQ GH1 IGF1 LEP RETN
9
Endochondral Ossification 1
11.5 GH1 GHR IGF1
10
Signaling events mediated by PTP1B 1
11.33 LEP LEPR PRL
11
Growth hormone receptor signaling 66
Show member pathways
 11.22 GH1 GHR PRL
12
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.02 LEP LEPR POMC
13
Adipocytokine signaling pathway 37
10.94 ADIPOQ AGRP LEP LEPR NPY POMC
14
Syndecan-3-mediated signaling events 1
10.78 AGRP POMC
15
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
10.32 CRH POMC
Sources

GO Terms for Anorexia Nervosa

About this section

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 ADIPOQ AGRP BDNF CCK CRH GH1
2 neuronal cell body GO:0043025 9.65 AGRP CCK CRH GHR HTR2A
3 extracellular space GO:0005615 9.53 ADIPOQ AGRP BDNF CCK CRH GH1
4 endosome lumen GO:0031904 9.32 GH1 PRL
5 growth hormone receptor complex GO:0070195 9.16 GH1 GHR

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.88 GH1 LEP SLC6A4
2 female pregnancy GO:0007565 9.87 CRH LEP PRL
3 neuropeptide signaling pathway GO:0007218 9.87 AGRP NPY POMC PYY
4 response to nutrient GO:0007584 9.86 ADIPOQ LEP SLC6A4
5 memory GO:0007613 9.85 BDNF HTR2A SLC6A4
6 regulation of blood pressure GO:0008217 9.85 LEP NPY POMC
7 circadian rhythm GO:0007623 9.84 ADIPOQ AGRP LEP SLC6A4
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 GH1 IGF1 LEP
9 glucose metabolic process GO:0006006 9.83 ADIPOQ GHRL LEP
10 response to insulin GO:0032868 9.83 AGRP IGF1 LEP RETN
11 feeding behavior GO:0007631 9.8 AGRP NPY PYY
12 hormone-mediated signaling pathway GO:0009755 9.8 AGRP GHR GHRL
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 GH1 GHR IGF1 LEP
14 glucose homeostasis GO:0042593 9.8 ADIPOQ IGF1 LEP LEPR POMC
15 regulation of multicellular organism growth GO:0040014 9.76 GHR IGF1 PRL
16 eating behavior GO:0042755 9.75 AGRP CCK LEP
17 hormone metabolic process GO:0042445 9.71 GHR LEP
18 positive regulation of insulin receptor signaling pathway GO:0046628 9.71 IGF1 LEP
19 central nervous system neuron development GO:0021954 9.7 LEP NPY
20 energy reserve metabolic process GO:0006112 9.7 LEP LEPR
21 insulin-like growth factor receptor signaling pathway GO:0048009 9.7 GHR IGF1
22 negative regulation of gluconeogenesis GO:0045721 9.69 ADIPOQ LEPR
23 regulation of feeding behavior GO:0060259 9.69 AGRP LEPR
24 sexual reproduction GO:0019953 9.69 LEP LEPR
25 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.69 GH1 GHR PRL
26 growth hormone receptor signaling pathway GO:0060396 9.68 GH1 GHR
27 positive regulation of growth GO:0045927 9.68 GH1 GHRL
28 negative regulation of appetite GO:0032099 9.67 CCK LEP
29 leptin-mediated signaling pathway GO:0033210 9.67 LEP LEPR
30 positive regulation of multicellular organism growth GO:0040018 9.67 GH1 GHR GHRH GHRL
31 positive regulation of growth hormone secretion GO:0060124 9.66 GHRH GHRL
32 regulation of bone remodeling GO:0046850 9.65 LEP LEPR
33 positive regulation of feeding behavior GO:2000253 9.65 AGRP GHRL
34 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.65 GH1 GHRH IGF1
35 growth hormone secretion GO:0030252 9.64 GHRH GHRL
36 bone mineralization involved in bone maturation GO:0035630 9.64 IGF1 LEP
37 positive regulation of corticotropin secretion GO:0051461 9.63 CRH GHRL
38 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.63 ADIPOQ CCK GH1 GHR HTR2A IGF1
39 positive regulation of JAK-STAT cascade GO:0046427 9.62 GH1 GHR LEP PRL
40 positive regulation of appetite GO:0032100 9.61 GHRL NPY
41 positive regulation of cortisol secretion GO:0051464 9.61 CRH GHRL
42 regulation of appetite GO:0032098 9.61 NPY POMC PYY
43 negative regulation of glucagon secretion GO:0070093 9.6 CRH LEP
44 bone growth GO:0098868 9.56 LEP LEPR
45 adult feeding behavior GO:0008343 9.56 AGRP GHRL LEP NPY
46 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.55 CRH GHRL
47 regulation of signaling receptor activity GO:0010469 9.47 ADIPOQ AGRP BDNF CCK GH1 GHRH
48 response to nutrient levels GO:0031667 9.43 ADIPOQ GH1 GHRL IGF1 LEP PRL
49 G-protein coupled receptor signaling pathway GO:0007186 10.19 CCK CRH GHRH GHRL HTR2A NPY
50 cell-cell signaling GO:0007267 10.02 BDNF GHRH NPY POMC PYY

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.73 ADIPOQ AGRP CRH LEP NPY POMC
2 G-protein coupled receptor binding GO:0001664 9.46 GHRL NPY POMC PYY
3 neuropeptide hormone activity GO:0005184 9.43 AGRP CCK CRH NPY POMC PYY
4 hormone activity GO:0005179 9.4 ADIPOQ CCK CRH GH1 GHRL IGF1
5 prolactin receptor binding GO:0005148 9.37 GH1 PRL
6 growth hormone-releasing hormone activity GO:0016608 9.32 GHRH GHRL
Sources

Sources for Anorexia Nervosa

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....